MSB trading, page-2075

Alex Waislitz in the AFR today:

Which stocks are catching your eye?
I've been intimately associated with Mesoblast for more than a decade and recently recommended it to investors at the Sohn Conference in Tel Aviv. At one stage several years ago the company had a market capitalisation of more than $3 billion now it's $1 billion, yet today it has a commercialised product, it is generating sales revenue and has three potential multi-billion dollar medical treatments in early stage late trials. I believe Meso is destined to take its place as one of the world's truly great biotechs. It has promising late stage trials underway for treatments across heart failure and chronic lower back pain. While the board could have done a better job managing its Nasdaq listing, leadership structure and capital management it still represents exceptional value. I believe the wait is almost over and Meso may finally be about to deliver on its long held promise.